Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion ...

Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on pelabresib.

Eli Lilly agrees to pay $57 a share for Morphic, a 79% premium to the stock’s closing price of $31.84 on Friday.

Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced ...

Eli Lilly agreed to buy Waltham-based gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some of the ...

Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda ...

Eli Lilly has agreed to acquire Morphic Therapeutic for $3.2 billion, in a deal designed to expand the buyer’s chronic ...

Eli Lilly said Monday it will acquire Morphic Holding, a biotech developing a treatment for inflammatory bowel disease.

Eli Lilly on Monday announced a $3.2 billion all-cash deal to purchase Morphic and its pipeline of oral integrin therapies in ...

Eli Lilly acquires Morphic Holding for $3.2 billion, gaining a potential IBD treatment asset, MORF-057. Explore more details ...

Eli Lilly agreed to buy Morphic Holding for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of ...

July 8 (Reuters) - Eli Lilly (LLY.N), opens new tab agreed to buy Morphic Holding (MORF.O), opens new tab for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of ...